Clinical Trial Update: Efficacy and Safety of HRS-5965 in Patients With PNH Who Are Still Anemia After Anti-C5 Antibody Treatment [Phase 3]

View source ↗

Summary

Phase 3 clinical trial evaluating the efficacy and safety of HRS-5965 in Paroxysmal nocturnal hemoglobinuria patients who remain anemic after anti-C5 antibody t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paroxysmal Nocturnal Hemoglobinuria

Drugs mentioned

• HRS-5965

Snippet

Sponsor: Chengdu Suncadia Medicine Co., Ltd. | Conditions: Paroxysmal Nocturnal Hemoglobinuria | Phase 3 | Status: COMPLETED